This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
Gavi Board Decisions Outline “Year of Renewal” for Vaccine Alliance

- Board underlines commitment to end backsliding in routine immunisation, catching up coverage and reaching zero-dose children as the Vaccine Alliance’s core priorities for the remainder of the current 2020–2025 strategic period.
- The Board also affirmed Gavi’s critical role in fighting outbreaks and pandemic preparedness and response, and approved its current COVID-19 vaccination strategy – alongside support for exploring future integration with Gavi core programming.
- New initiatives approved include a relaunch of HPV vaccination, an innovative plan to support vaccine manufacturing in Africa and other regions, and support to countries and communities confronting multiple global challenges.

Geneva, 8 December 2022 – The Board of Gavi, the Vaccine Alliance today approved an evolution of its current 5-year programme strategy that will see renewed focus on routine immunisation and reaching zero-dose children, new vaccine introductions, a strengthened Alliance role in outbreak and pandemic preparedness and response, alongside continued COVID-19 vaccinations in the 92 lower income countries supported by the Gavi COVAX Advance Market Commitment. Professor José Manuel Barroso, Chair of the Board, was confirmed for a second, three-year term.

The two-day meeting, which concluded today, also approved a relaunch of the Alliance’s HPV vaccination programme. An ambitious plan to support sustainable regional vaccine manufacturing, particularly in Africa, was also adopted.

The Board also gave a green light to leverage Gavi’s decades-long experience combatting the continuum of outbreaks, epidemics and pandemics, including with the recent learnings from COVAX, for pandemic preparedness and response (PPR) – in particular working towards equitable access to outbreak and pandemic vaccines, strengthening health systems, accelerating at-risk innovative financing and supporting diversification of global vaccine manufacturing.

A decision to continue ensuring COVID-19 vaccines are accessible to the 92 AMC countries was also approved by the Board. While the current priority remains to help countries raise coverage levels and boost high risk groups, the Board also endorsed plans to start preparing now for future evolutions of the virus. While COVAX continues to have in place plans for worst case scenarios, the Board agreed, in principle, to explore integrating future COVID-19 vaccinations into Gavi’s core programming – in a bid to improve synergies, be more responsive to countries’ needs and reduce the additional burden a specialized emergency response places on countries. This approval in principle will help Gavi engage with countries and partners on what shape a future programme would take, while also remaining flexible in case of further developments in 2023.

“Never before have Gavi-supported countries administered as many vaccines as the billions of doses they did in 2021. Yet routine immunisation has been impacted hard by the pandemic for two consecutive years and it is essential that we help countries to address this. The decisions taken at this week’s meeting will help the Vaccine Alliance enter a Year of Renewal; not only its historical mission to
leave no one behind with immunisation but of the Alliance itself, introducing new innovations and ways of working learned from the pandemic,” said Professor José Manuel Barroso, Chair of the Board of Gavi.

**Further details on the decisions made at the Board Meeting include:**

- **Gavi’s Board expressed overwhelming support for the relaunch of the HPV vaccine programme with over US$ 600 million investment.** The money will go towards funding vaccines, strengthening health systems and providing technical and learning support. With cervical cancer causing 342,000 deaths in 2020, 90% of which occurred in low- and middle-income countries, the HPV vaccine is one of the most impactful vaccines in Gavi’s portfolio. With the new funding in place, the Alliance has set an ambitious goal to reach over 86 million girls by 2025, aiming to avert over 1.4 million future deaths from cervical cancer.

- A plan to support the **development of a regionally diversified vaccine manufacturing ecosystem** was also approved. Based on three pillars; support for strategic antigen selection by manufacturers/countries, market shaping and demand creation, the initiative represents a major step forward in addressing one of the critical challenges faced during the pandemic: how to ensure all regions of the world have the ability to manufacture vaccines. The initiative, supported by the African Union, Africa CDC, G7 and other stakeholders, also envisages the possibility of a fourth pillar, the design of a new financial instrument in the form of an Advance Market Commitment (AMC) for African vaccine manufacturing. This will be developed over the coming year, for potential approval and launch in 2023.

- Recognising that countries and communities face increased fragility and multiple challenges, the Board sought to balance ensuring access with sustainability through Gavi transition and co-financing policies. **The Board extended timeframes for countries scheduled to transition out of Gavi support, put in place lower, time-limited, co-financing requirements for new malaria vaccines, extended the Gavi eligibility and co-financing exemptions for inactivated polio vaccine (IPV) in support of polio eradication efforts, and confirmed zero co-financing requirements for outbreak response and refugee populations currently not integrated into national plans.**

“Gavi’s mission, working together as Alliance to deliver unparalleled impact, has always been to help countries protect their populations through immunisation. As we move out of the emergency phase of the pandemic, this will mean catching up on essential and sustaining COVID-19 vaccinations, helping them plan and prepare for the increasing occurrence of outbreaks due to climate change and growing populations – and looking further ahead, putting in place a global health response that will enable us to address future pandemics and global health security threats much more effectively,” said Dr Seth Berkley, CEO of Gavi.

**Appointments and Process Updates**

In addition, a number of appointments were made or reconfirmed:

- Prof José Manuel Barroso was reappointed for a new term as Board Chair.
- Mphu Ramatlapeng, Gabriella Fésüs, Saad Omer and Andrew (Drew) Otoo were appointed to join the board on 1 January 2023. They replace Margaret (Peggy) Hamburg, Bernhard Braune, Marta Nunes and Roger Connor respectively. John Arne Røttingen was reappointed to the board.
- Jérémie Forrat-Jaime, Rhoda Wanyenze and Joan Benson were appointed, and Francesca Manno and Joris Jurriëns were reappointed, as alternate members. Yibing Wu was appointed as Chair of the Investment Committee.
The Rockefeller Foundation and Digital Square at PATH Commit $5M to Strengthening Data-Driven Health Systems & Global Immunizations

Dec 07 2022 Press Releases

NEW YORK | December 7, 2022 – The Rockefeller Foundation and PATH announced the Digital Results Improve Vaccine Equity and Demand (DRIVE Demand) project, a two-year, US$5 million partnership with PATH’s Digital Square initiative to deploy and expand the use of digital health tools in Jamaica, Mali, Tanzania, Thailand, Uganda, and Zambia. Through DRIVE Demand, the partners aim to help ministries of health utilize digital technologies to understand, track, and influence demand for immunizations. Ultimately, it will support target countries’ effort to reach national Covid-19 and routine immunization targets, while strengthening data-driven health systems in Asia, the Caribbean, and Sub-Saharan Africa...

The six focus countries were chosen based on an evaluation of their responses to Covid-19, including: vaccine demand; vaccination rates (both low and high); use of existing open source global good digital health platforms or systems; and intersection with The Rockefeller Foundation’s Vaccination Access Network (VAN). The results of this evaluation led to a country-by-country approach to activity generation, which was created with government leaders to ensure that the program aligned with government priorities and responded to individual country needs...

In addition to supporting Covid-19 vaccination efforts, the DRIVE Demand project will also guide partners through the process of digitizing existing health record systems and integrating software while applying learnings from Covid-era innovations to routine immunizations and future pandemic preparedness...

The funding for DRIVE Demand is part of The Rockefeller Foundation’s Global Vaccination Initiative (GVI), a two-year, $55 million effort launched in April 2022 to support country-led Covid-19 immunization campaigns in Africa, Asia, Latin America, and the Caribbean.

About Digital Square
Digital Square is a PATH-led initiative funded by the Rockefeller Foundation, the United States Agency for International Development (USAID), the Bill & Melinda Gates Foundation, and a consortium of other partners to advance digitally enabled health services around the world to help close the health equity gap. Since its inception in 2016, Digital Square has raised nearly $115M to catalyze a range of digital health investments in support of the adoption, adaptation, and scaling of interoperable digital technologies to improve global health equity. Digital Square’s coalitions, resources, and community of mature digital public goods for health (global goods) support large-scale, high-quality, sustainable implementations of digital health interventions.
WHO
8 December 2022

Overview

The results of the report clearly show that in 2020, a year dominated by the emergence of COVID-19 and its associated health and economic crises, governments around the world rose to the challenge. **Sharp increases in government spending on health at all country income levels underpinned the rise in health spending to a new high of US $9 trillion (approximately 11% of global GDP).** Government health spending generally increased and offset declines in out-of-pocket spending. Importantly, the rise in government health spending was part of a much broader fiscal response to the pandemic. In high income and upper-middle income countries social protection spending also increased sharply as governments attempted to cushion populations from the economic impacts of COVID-19. In contrast to health and social protection, growth in education spending was relatively subdued. Countries face the further challenge of sustaining increased public spending on health and other social sectors in the face of deteriorating macroeconomic conditions and rising debt servicing. This also includes the challenge of sustaining external support for low income countries, which is essential for reducing ensuring poverty, ensuring access to health services and strengthening pandemic preparedness.

**Higher health spending in response to a global pandemic**
- In 2020, global spending on health reached US$ 9 trillion, or 10.8% of global gross domestic product (GDP), and was highly unequal across income groups.
- Across countries, health spending in 2020 rose in per capita terms and as a share of GDP across all income groups.
- Government spending was the main driver of the increase in total health spending from 2019 to 2020. Per capita government spending on health increased in all income groups and rose faster than in previous years.
- Health spending as a share of total government expenditure, an indicator of the priority given to health, increased from 2019 to 2020 in all income groups except high income countries.
- Out-of-pocket spending per capita fell during the first year of the pandemic, which may reflect reduced health service utilization.
- External aid continued to play a critical role in low income countries. From 2019 to 2020, per capita health spending from aid increased marginally in low income countries.

---

**World malaria report 2022**

Global Report - 8 December 2022 :: 372 pages
PDF: https://apps.who.int/iris/rest/bitstreams/1484818/retrieve

**Overview**

Each year, WHO’s World malaria report offers in-depth information on the latest trends in malaria control and elimination at global, regional and country levels. The report highlights progress towards global targets and describes opportunities and challenges for curbing and eliminating the disease.

This year’s report includes 3 new sections on: (1) global and regional initiatives launched in 2021 and 2022; (2) global malaria surveillance and country-level case studies on surveillance systems assessments; and (3) research and development. The report also includes an expanded section on threats to malaria control, with a focus on the declining effectiveness of insecticide-treated mosquito nets.
Despite continued impact of COVID-19, malaria cases and deaths remained stable in 2021

News release Geneva, Switzerland
8 December 2022

New data released today by the World Health Organization (WHO) show that countries around the world largely held the line against further setbacks to malaria prevention, testing and treatment services in 2021.

According to this year’s World malaria report, there were an estimated 619 000 malaria deaths globally in 2021 compared to 625 000 in the first year of the pandemic. In 2019, before the pandemic struck, the number of deaths stood at 568 000.

Malaria cases continued to rise between 2020 and 2021, but at a slower rate than in the period 2019 to 2020. The global tally of malaria cases reached 247 million in 2021, compared to 245 million in 2020 and 232 million in 2019.

“Following a marked increase in malaria cases and deaths in the first year of the COVID-19 pandemic, malaria-affected countries redoubled their efforts and were able to mitigate the worst impacts of Covid-related disruptions to malaria services,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “We face many challenges, but there are many reasons for hope. By strengthening the response, understanding and mitigating the risks, building resilience and accelerating research, there is every reason to dream of a malaria-free future.”...

Pharmaceutical industry statement delivered at CBD COP 15 meeting regarding Digital Sequence Information and the need for special measures for pathogen sharing

Published on: 07 December 2022

IFPMA is grateful for the opportunity to participate in the COP15 negotiations. The importance of biodiversity conservation and sustainable use has become more and more pressing, and IFPMA, the body representing the innovative pharmaceutical industry in official relations with the ECOSOC/United Nations, hopes that a successful negotiation of the Post-2020 Global Biodiversity Framework will allow countries to come together to address biodiversity loss across the globe.

The COVID-19 pandemic has, however, highlighted flaws in the implementation of the Nagoya Protocol that greatly restrict the speed, certainty, and ease at which pathogens can be shared. The negative impact of the implementation of the Nagoya Protocol on public health has been significant and could have even more serious effects. We’ve seen these negative consequences in the sharing of seasonal and pandemic influenza, SARS-CoV-2, Zika, Monkeypox, Japanese Encephalitis, Foot and Mouth Disease, African Swine Fever, and bacterial isolates important for assessing antimicrobial resistance. The way many countries have decided to implement the Nagoya Protocol domestically has led to delays of up to 18 months in the sharing of pathogens, or stopped it altogether.

Pathogens cannot be treated in the same way as other genetic resources – delays in accessing pathogens in pre-pandemic and pandemic situations can have devastating effects on human lives as well as society at large. Ensuring immediate and unhindered
pathogen sharing, through a public health exemption to access and benefit (ABS) rules, is critical for the future of public health.

According to our analysis, an overwhelming majority of Parties to the Nagoya Protocol have not implemented their obligation under Article 8(b) of the Protocol, with only 12 jurisdictions out of 137 having implemented some form of public health exemption. More often than not, this exemption does not provide clarity or speed up the sharing of pathogens. This has weakened legal certainty for R&D despite the willingness and efforts of pharmaceutical companies, research laboratories and the WHO to work with national governments.

Regarding negotiations on digital sequence information (DSI), any policy option or mechanism currently under consideration by member states must include an exemption for pathogens in order to prevent delays in the sharing of pathogens. The current options, as they are formulated, could have serious consequences for the surveillance of pathogens, as they are not specially tailored for the world of public health and thus risk undermining ongoing and future pandemic preparedness and response efforts.

The above points demonstrate that (i) the current ABS system for genetic resources is not working and (ii) that pathogens require special expedited measures. These two issues must be resolved before any new DSI system is implemented. IFPMA is of the firm belief that no ABS system, as proposed, should apply to DSI and that pathogens must be excluded from the scope of the CBD.

WHO Member States agree to develop zero draft of legally binding pandemic accord in early 2023
7 December 2022  News release  Geneva
- Countries meet for three days to agree next steps toward historic legal instrument, rooted in the WHO Constitution, designed to protect world from future pandemics.
- During discussions, Member States call for global agreement that takes into account equity, promotes preparedness, ensures solidarity and respects sovereignty.
- Zero draft of the pandemic accord to be ready for negotiations by Member States starting February 2023.

Member States of the World Health Organization today agreed to develop the first draft of a legally binding agreement designed to protect the world from future pandemics. This "zero draft" of the pandemic accord, rooted in the WHO Constitution, will be discussed by Member States in February 2023.

Today’s agreement by the Intergovernmental Negotiating Body (INB), comprised of WHO’s 194 Member States, was a milestone in the global process to learn from the COVID-19 pandemic and prevent a repeat of the devastating impacts it has had on individuals and communities worldwide. The INB gathered at WHO headquarters in Geneva from 5-7 December for its third meeting since its establishment in December 2021, following a special session of the World Health Assembly.

The Body today agreed that the INB’s Bureau will develop the zero draft of the pandemic accord in order to start negotiations at the fourth INB meeting, scheduled to start on 27
February 2023. This draft will be based on the conceptual zero draft and the discussions during this week’s INB meeting. The INB Bureau is comprised of six delegates, one from each of the six WHO regions, including the Co-Chairs Mr Roland Driece of the Netherlands and Ms Precious Matsoso of South Africa...

::::::
::::::

China – COVID Response

Editor’s Note:
We have noted over many months that official China public health channels have severely limited reporting on COVID response and policy. The recent and still emerging shift from the zero-COVID strategies of the last few years, apparently triggered by mass protests across the country and other pressures, has triggered significant global media coverage and analysis.

The clash of political power and evidence-based public health policy has occurred at too many points in global pandemic response and in different national contexts, including the U.S. Given the apparent milestone reached in the PRC context, we include a small selection of media reports below [clearly not exhaustive, clearly Global North-weighted, but hopefully indicative].

![China’s COVID Failure](image-url)
Leaders / China and the pandemic

Xi Jinping’s zero-covid policy has turned a health crisis into a political one
Caught between raging disease and unpopular and costly lockdowns, he has no good fix

CHINA INVENTED covid-19 lockdowns. During the first weeks of the pandemic, the government of Xi Jinping corralled tens of millions of people to stop the disease spreading out of Wuhan. Almost three years later, lockdowns have become China’s undoing. A combination of protests and rising cases means that Mr Xi will have to navigate between mass lockdowns and mass infection—and possibly end up with both. The coming months will pose the biggest threat to his rule since he came to power in 2012 and the biggest threat to the authority of the Communist Party since the protests around Tiananmen Square in 1989...

Financial Times
10 Dec 2022
Opinion - Chinese politics & policy

China faces an uncertain future in the zero-Covid endgame
Despite official triumphalism, rolling back the policy could see the health system overwhelmed

James Kynge

The Chinese took the art of cryptic demonstrations to new heights last week. Well aware of the perils of protest in an authoritarian state with about 600mn surveillance cameras, the crowds of people who turned out to criticise Beijing’s stifling “zero-Covid” regime did so in a number of ingenious ways.

One group of students from the elite Tsinghua University in Beijing held aloft sheets of paper bearing a mathematical equation that describes the expansion of the universe. The message, it turned out, was that the equation had been developed by Alexander Friedmann, whose name sounds like “Free Man” — and freedom is what the protesters were calling for...

The protests, which took place in more than 20 cities, have ended. But the demands of the demonstrators to unwind zero-Covid are being met, at least in part. After nearly three years of subjecting 1.4bn people to a regime of mass testing, travel curbs and rolling urban lockdowns, Beijing is lifting or relaxing restrictions in cities across the country.

These are certainly momentous times. But it is unlikely that the sudden policy shift represents meek acquiescence towards the street protests by Xi Jinping, China’s strongman leader. A much more plausible explanation is that the change of heart was prompted by a build-up of discontent within the vast Communist party hierarchy as the economy stuttered, youth unemployment surged and education was disrupted...

The big risks, however, concern what comes next. China is in uncharted territory: a dash towards herd immunity could cause the deaths of as many as 1mn people in a massive “winter wave” of infections, according to recent mathematical modelling by Wigram Capital Advisors, an Asia-focused macroeconomic advisory group.

Under a scenario in which China’s leadership continues to roll back zero-Covid, the national health system would quickly become overwhelmed. With daily fatalities reaching as high as 20,000 in mid-March, demand for intensive care units would peak at 10 times higher than capacity by late March, according to the Wigram Capital Advisors’ model. Aside from the human cost, the political fall out could
be intense. Xi has been hailed by the state media as the “commander-in-chief of the people’s war against Covid”. He has boasted that China’s response to the pandemic — which has kept officially reported total deaths down to the very low number of 5,235 — demonstrated the “superiority” of the country’s system.

If deaths start to rise sharply, it will not only mark a personal failure for Xi. It will also raise questions about his judgment and the ability of China’s highly centralised power structure to make wise decisions...


Financial Times
09 Dec 2022
China’s disappearing data stokes fears of hidden Covid wave
Low official case number and death toll puzzle analysts after Beijing lifts Covid testing requirements
Edward White in Seoul and Qianer Liu in Hong Kong

China is under-reporting coronavirus cases and fatalities, obscuring the scale and severity of the health crisis just as the world’s most populous country enters its deadliest phase of the pandemic, analysts warn.

Official statistics on Friday revealed no new deaths and only 16,363 locally transmitted coronavirus cases in China, less than half the peak caseload reported last month.

That is despite a stunning U-turn over the past week to relax President Xi Jinping’s heavy-handed pandemic controls, which means the virus is certain to spread.

The sweeping changes to Xi’s zero-Covid policy allow asymptomatic or mild cases to isolate at home rather than in centralised quarantine, and slashed China’s mass testing and contact tracing requirements.

The sudden reversal came weeks after Covid-19 cases hit a record high of more than 40,000 a day, with every region of the country reporting an Omicron outbreak.

Despite the official numbers suggesting the caseload had halved, Raymond Yeung, China economist at ANZ bank, said that on-the-ground observations indicated some cities, including Baoding, in the northern province of Hebei, already had “high infection numbers”. More big cities, he said, would soon endure similar levels of infections.

“Like Hong Kong, the actual infection data will no longer be informative. As the ‘official’ infection figures decline, the government can eventually claim their success against the virus,” Yeung said.

The situation echoes the dearth of official information during the disastrous initial outbreak in Wuhan nearly three years ago. Local officials and analysts warned that the reduced testing, as well as gaps in reporting of both cases and deaths, would make it harder to assess the risk to the world’s second-biggest economy.
“The behaviour of case numbers is very similar to 2020, where we had one [to] two weeks with genuine case numbers, before the veil was drawn,” said Rodney Jones, principal at Wigram Capital Advisors, an Asia-focused macroeconomic advisory group.

“We have no idea whether we will see actual case data again, and whether the sharp downshift in cases reflects reduced testing . . . or political management of the case data,” Jones added.

A critical missing piece of information is the rate of positive tests, which is important for determining actual infection. Nor is the real-time effective R value published, depriving observers of a vital measure of the rate at which the disease is spreading.

There are also discrepancies between Chinese regions in how cause of death is determined and the definition of “symptomatic”. In some cities, including Shanghai, a chest scan is required before Covid diagnosis.

Xi’s decision to loosen strictures has led to fears of an unparalleled wave of infections and a sharply rising death toll. Wigram has projected as many as 1mn deaths over the winter months...

New York Times
December 9, 2022 08:14 am ET
China

China’s Covid-19 Reversal Sparks Rush for Medicines, Vaccines

After years saying the virus is too deadly to live with, leaders now risk a lethal surge in infections.

Selina Cheng

December 8, 2022 08:33 am ET

China

China Braces for Deadly Covid Wave After Loosening Controls

Strained hospitals and the country’s poor vaccination rates could lead to over a million deaths, according to some public health experts. “It will put unprecedented strain on the Chinese health system,” a scientist said.

Sha Hua and Liyan Qi

Appeared in the Dec 09, 2022, print edition as 'Beijing Is Bracing for a Deadly Covid-19 Wave'

-----

-----

-----

PHEIC

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates

Last update: 9 Dec 2022

Confirmed cases :: 643 875 406
Confirmed deaths :: 6 630 082
Vaccine doses administered: 12 998 974 878

-----

Weekly epidemiological update on COVID-19 – 7 December 2022

Overview

Globally, the number of new weekly cases remained stable (-3%) during the week of 28 November to 4 December 2022 as compared to the previous week with just under 3 million new cases reported. The number of new weekly deaths decreased by 17% as compared to the previous week with about 7800 fatalities reported. As of 4 December 2022, over 641 million confirmed cases and 6.6 million deaths have been reported globally....
UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 10 Dec 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

| 50 | vaccines approved for use by at least one national regulatory authority | 11 | vaccines in WHO’s Emergency Use Listing |
| 1.87bn | doses shipped through COVAX to 146 countries | $2 - $120 | reported vaccine price range per dose |
| 18.0bn | doses secured globally | 46K | novel oral antiviral therapeutic treatments arrived in 9 countries |

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 10 Dec 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability
COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

COVID-19 Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

DEC 10 2022  |  COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports  |  DATA

Global COVID-19 Figures: 121M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 13.0B

Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 390M
Other Delivered (Number of Doses): 420M
Total Delivered (Number of Doses): 800M
Total Administered (Number of Doses): 540M

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.
The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 10 Dec 2022: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.

Our World in Data
:: 68.6% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.04 billion doses have been administered globally, and 2.35 million are now administered each day.
:: 24.9% of people in low-income countries have received at least one dose.

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged. Donut charts are ordered by proportion of pledged doses shipped.

United States: 84% shipped
China: 76% shipped
Germany: 69% shipped
France: 69% shipped
Spain: 68% shipped
United Kingdom: 66% shipped
Italy: 57% shipped
Australia: 45% shipped
Japan: 45% shipped
Canada: 44% shipped

Remaining: 669,399,048
Total Shipped: 1,559,199,430

Data updated on December 9th, 2022

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/
U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
Letter to U.S. Governors from HHS Secretary Xavier Becerra on COVID-19, Flu, and RSV
Resources
December 9, 2022 | News Release

Statement from HHS Secretary Xavier Becerra on CDC’s Recommendation of the Updated COVID-19 Vaccines for Young Children
December 9, 2022 | News Release

Statement From HHS Secretary Becerra on mpox
December 2, 2022 | News Release

FDA
Press Announcements
Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age
December 8, 2022
Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency
*News & Press Releases*

**News:** ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2 (new)
Last updated: 09/12/2022

**News:** ECDC and EMA collaborate on vaccine safety and effectiveness monitoring studies (new)
Last updated: 08/12/2022

**News:** ETF concludes that bivalent original/Omicron BA.4-5 mRNA vaccines may be used for primary vaccination (new)
Last updated: 06/12/2022

--------------------

European Centre for Disease Prevention and Control

*News [Selected]*

**News**
**Ebola outbreak in Uganda, as of 06 December 2022**
Epidemiological update - 9 Dec 2022

**News**
**Weekly COVID-19 country overview**
Epidemiological update - 9 Dec 2022

**News**
**Joint ECDC-WHO Europe COVID-19 surveillance bulletin**
Epidemiological update - 9 Dec 2022

**News**
**ECDC and EMA collaborate on vaccine safety and effectiveness monitoring studies**
Press release - 8 Dec 2022

--------------------

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
[https://africacdc.org/covid-19-vaccination/](https://africacdc.org/covid-19-vaccination/)
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.
China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations.]

**China’s Xi unwilling to accept vaccines despite protests, U.S. official says**
Reuters
1 hour ago

**Beijing, Shenzhen loosen more COVID curbs as China fine-tunes policy**
Reuters
9 hours ago

---

**PHEIC**

**Mpxox**

Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

1 December 2022

**Multi-country outbreak of mpxox, External situation report #11 - 1 December 2022**

*Highlights*

:: Following a series of consultations with global experts, WHO will begin using the term “mpox” as the preferred name for the disease of monkeypox. Both names will be used simultaneously for one year while “monkeypox” is phased out. During the week of 21 to 27 November 2022, the number of mpox cases reported globally continued to decline.
:: In the week commencing 21 November, the Eastern Mediterranean Region has reported six new cases after five consecutive weeks without cases. These are retrospective reports of cases diagnosed between 1 October and 25 November 2022.
:: Since the last situation report published on 16 November, 1696 new cases (2.1% increase in total cases) and five new deaths have been reported.
:: Since the beginning of the outbreak, a high prevalence of HIV infection (52%; 14 573/28 006) has been reported among cases with known HIV status.
:: The proportion of cases among females has been gradually increasing since the beginning of the outbreak, reaching 6.7% as of 20 November 2022

---

**PHEIC**

**Polio**

Polio this week as of 07 December 2022 - GPEI
:: In Africa, to reinvigorate political attention and action on immunization across the continent, H.E. Macky Sall, Chair of the African Union and President of the Republic of Senegal, will bring together Heads of State, civil society organizations, and other key stakeholders at the Forum on Immunization and Polio Eradication on 10 December in Dakar, Senegal, to remobilize leadership around the Addis Declaration on Immunization.

:: PBS feature on polio and immunization in DR Congo: the piece focuses on efforts to provide routine immunization to children, including during the pandemic, highlighting how local healthcare workers are responding to various challenges.

:: In Pakistan, a high-level delegation led by Polio Oversight Board (POB) Chair Dr Chris Elias, WHO Regional Director for the Eastern Mediterranean Dr Ahmed Al-Mandhari and UNICEF Regional Director George Laryea-Adjei, concluded there is unprecedented support and commitment to ending polio in the country in 2023. More.

Summary of new polioviruses this week:
- Pakistan: two WPV1 positive environmental samples
- Benin: three cVDPV2 cases and two positive environmental samples
- CAR: one cVDPV2 positive environmental sample
- Ghana: one cVDPV2 case and one positive environmental sample
- Madagascar: three cVDPV1 cases and 13 positive environmental samples
- Mozambique: two cVDPV1 cases
- Niger: two cVDPV2 cases and four positive environmental samples
- Togo: one cVDPV2 case

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
No new digest content identified.

Northern Ethiopia
Ethiopia - Situation Report, 6 Dec 2022

Somalia
No new digest content identified.

Ukraine
Highlights Last Updated: 29 Nov 2022

WHO & Regional Offices [to 10 Dec 2022]
https://www.who.int/news
Selected News/Announcements/Statements
9 December 2022
News release
Report signals increasing resistance to antibiotics in bacterial infections in humans and need for better data

9 December 2022
News release

Ebola trial candidate vaccines arrive in Uganda in record 79 days after outbreak declared

9 December 2022
Departmental news

Moving WHO guidance on antibiotics into the heart of clinical practice

8 December 2022
News release

Despite continued impact of COVID-19, malaria cases and deaths remained stable in 2021

8 December 2022
Departmental news

The European Union and WHO further enhance their partnership for stronger pandemic preparedness and response

7 December 2022
News release

WHO Member States agree to develop zero draft of legally binding pandemic accord in early 2023

:::

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region
:: COVID-19 burden lessens in Africa, vigilance crucial as year-end season begins
08 December 2022 Brazzaville – While Africa is witnessing its lowest level of new COVID-19 cases since the onset of the pandemic, a recent four-week rise—the first such sustained increase in four months—underscores the criticality of maintaining vigilance as the end-year holiday seasons sets in...

:: Bolstering Africa’s health emergency readiness and response
06 December 2022 Brazzaville – The World Health Organization (WHO) Regional Office for Africa in partnership with Africa Centres for Disease Control and Prevention, West African Health Organization, United States Centers for Disease Control and Prevention, UK Health Security Agency, Robert Koch Institute and the Bill and Melinda Gates Foundation today kicked off the region’s largest public health emergency operation centre (PHEOC) simulation exercise to step up readiness to respond to public health emergencies, with 36 countries taking part in the two-day functional exercise.

WHO Region of the Americas PAHO
:: Report signals increasing resistance to antibiotics in bacterial infections in humans and need for better data
9 December 2022, GENEVA – A new World Health Organization (WHO) report reveals high levels of resistance in bacteria, causing life-threatening bloodstream infections, as well as increasing resistance
to treatment in several bacteria causing common infections in the community based on data reported by 87 countries in 2020. For the first time, the...
Overview
This document summarizes the results of the WHO-commissioned full value proposition for new tuberculosis (TB) vaccines. The assessment was commissioned to provide early evidence for national and global decision-makers involved in TB vaccine development and implementation, who include stakeholders involved in vaccine research, financing, regulation and policy-making, manufacturing, introduction and procurement. The goal is to accelerate development of effective vaccines against TB and their rapid introduction into countries.

8 December 2022
Improving the usability and impact of WHO guidelines: report of a WHO workshop

8 December 2022
UNICEF and WHO joint programme on mental health and psychosocial well-being and development of children...

CDC/ACIP [U.S.] [to 10 Dec 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases

CDC Studies Support Mpox Vaccine as Safe and Effective
December 9, 2022 Studies show vaccinated people have substantially less risk for contracting mpox compared with those who are unvaccinated and identified no major safety concerns after nearly 1 million doses administered.

CDC Expands Updated COVID-19 Vaccines to Include Children Ages 6 Months through 5 Years
December 9, 2022 Following FDA action, today CDC expanded the use of updated (bivalent) COVID-19 vaccines for children ages 6 months through 5 years.

Transcript: CDC Media Telebriefing - Update on Respiratory Disease Circulation
December 8, 2022
... As we are all aware, nationally, we are seeing elevated levels of respiratory viruses including RSV, flu and COVID-19. Especially for RSV and flu, these levels are higher than we generally see this time of year. Levels of flu like illness, which includes people going to the doctor with a fever and a cough or sore throat are at either high or very high levels in 47 jurisdictions and that is up from 36 jurisdictions just last week. CDC estimates that since October 1, there have already been at least 8.7 million illnesses, 78,000 hospitalizations and 4500 deaths from flu. Flu hospital admissions reported through HHS's hospital surveillance system, which were already high for this time of year have nearly doubled during the last reporting period. Compared to the week prior hospitalizations for flu continue to be the highest we have seen at this time of year in a decade, demonstrating the significantly earlier flu season we are experiencing...
ACIP Meetings
Next ACIP Meeting
No 2022 meetings identified.

::::::

MMWR Weekly: Current Volume (71)
December 9, 2022 / No. 49
PDF of this issue
- Progress Toward Poliomyelitis Eradication — Afghanistan, January 2021–September 2022
- Human Rabies — Texas, 2021
- Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak — United States, May 22–October 21, 2022
- Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022

::::::

Coronavirus Disease 2019 (COVID-19) - CDC
Announcements/reports/data summaries.

::::::

Africa CDC [to 10 Dec 2022]
http://www.africacdc.org/
News
Africa CDC convenes public health officials and experts to prepare the continent to respond to future outbreaks
5 December 2022
Public health officials, experts, researchers, and scientists around Africa will gather at a major conference at the African Union Commission in Addis Ababa, Ethiopia, this week to take stock of how ready, in a post-COVID-19 world, African countries are to face up to the next disease threat.

'Beyond COVID-19: Pathogen Genomics and Bioinformatics for Health Security in Africa’ will be hosted by the Africa Centres for Disease Control and Prevention (Africa CDC), the autonomous health institution of the African Union (AU). The meeting will be held at the AU's Headquarters in Addis Ababa from 29 November to 1 December 2022.

The event will draw around 120 public health officials, researchers, and scientists from 49 AU Member States, as well as local and international partners.

The symposium will, in particular, focus on the existing capacity along the full value chain of pathogen genomics and bioinformatics. This entails everything from the sequencing and analysing of disease-causing pathogens, to issues of supply chain, the generation and sharing of data, as well as international policies and agreements that govern how these processes should unfold.

Participants will review the progress, challenges and lessons from the rapid expansion of pathogen
genomics in Africa, through the Africa CDC’s Africa Pathogen Genomics Initiative (Africa PGI) and the work of other stakeholders over the past two years...

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China [to 10 Dec 2022]
http://en.nhc.gov.cn/
News
Dec 10: Daily briefing on novel coronavirus cases in China
On Dec 9, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 3,082 new cases of confirmed infections.

National Medical Products Administration – PRC [to 10 Dec 2022]
http://english.nmpa.gov.cn/
Chinese mainland reports 4,351 new local confirmed COVID-19 cases
2022-12-07
The Chinese mainland on Tuesday reported 4,351 locally transmitted confirmed COVID-19 cases, the National Health Commission said Wednesday.

China CDC Weekly Reports: Current Volume (4)
2022-12-09 / No. 49 WORLD ANTIBIOTIC AWARENESS WEEK ISSUE
View PDF of this issue
- Preplanned Studies: Dissemination of Antibiotic Resistance Genes Among Patients with Diarrhea — Freetown, Sierra Leone, 2018
- Commentary: National Antibiotic Resistance Strategy for Human Health in France
- Perspectives: Current and Future Landscape of the Antimicrobial Resistance of Nosocomial Infections in China
- Perspectives: Minimizing Risks of Antimicrobial Resistance Development in the Environment from a Public One Health Perspective

Organization Announcements

Paul G. Allen Frontiers Group [to 10 Dec 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.
Bill & Melinda Gates Medical Research Institute [to 10 Dec 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—their major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people.

News: Articles and Publications
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 10 Dec 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.

CEPI – Coalition for Epidemic Preparedness Innovations [to 10 Dec 2022]
http://cepi.net/
Latest News
CEPI boosts 'Coronavirus X' vaccine search with expanded VBI Vaccines deal
Agreement expands CEPI's world-leading portfolio of variant-proof coronavirus vaccines that could be deployed against COVID-19 as well as a future 'Coronavirus X'
06 Dec 2022

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 10 Dec 2022]
https://cioms.ch/
News; Publications
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 10 Dec 2022]
https://www.darpa.mil/news
News
Duke Global Health Innovation Center  [to 10 Dec 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP  [to 10 Dec 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
08 December 2022
EDCTP and ICGE B sign Memorandum of Understanding
By signing the MoU, the EDCTP Association and ICGEB agree that they shall encourage and promote cooperation in the following areas of mutual interest in sub-Saharan Africa:
1) Bringing high-level genomic engineering technology into EDCTP-funded networks in sub-Saharan Africa for optimising the fight against poverty-related infectious diseases
2) Joint activities in capacity development related to development of interventions against these diseases...

Emory Vaccine Center  [to 10 Dec 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative  [to 10 Dec 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.

Evidence Aid  [to 10 Dec 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
Interventions for noncommunicable diseases in humanitarian emergencies in low- and middle-income countries
Added December 6, 2022

Fondation Merieux  [to 10 Dec 2022]
Gavi [to 10 Dec 2022]
https://www.gavi.org/
News Releases
8 December 2022
Gavi Board Decisions Outline “Year of Renewal” for Vaccine Alliance
[See Milestones above for detail]

GHIT Fund [to 10 Dec 2022]
https://www.ghitfund.org/newsroom/press
Press Releases December 5, 2022
GHIT Fund Secures US$20 million pledge from Wellcome over 5 years

Global Fund [to 10 Dec 2022]
News & Stories
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 10 Dec 2022]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 10 Dec 2022]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 10 Dec 2022]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project [to 10 Dec 2022]
http://www.humanvaccinesproject.org/
News
IMMUNOME Report
Dec 08, 2022

Colin Carlson: Can Machine Learning Help Predict the Next Pandemic?

IAVI [to 10 Dec 2022]
https://www.iavi.org/
Latest News
FEATURES
December 7, 2022
Community-rooted science: a pathway to accelerating vaccine discovery

FEATURES
December 5, 2022
Meet the IAVI scientist on the cusp of developing a novel HIV vaccine candidate

ICRC [to 015 Oct 2022]
What’s New [Selected]
ICRC applauds UN Security Council’s adoption of a resolution protecting humanitarian activities
  New York (ICRC) - Today is an important day in the history of humanitarian action.
09-12-2022 | News release

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 10 Dec 2022]
Press Releases [Selected]
IFRC welcomes landmark U.N. Security Council resolution as a critical step towards scaling up humanitarian action in crisis-hit countries
  Geneva, 9 December 2021 – The International Federation of Red Cross and Red Crescent Societies (IFRC) welcomes the U.N. Security Council’s landmark resolution protecting humanitarian action in countries where U.N. sanctions apply.
  This resolution will facilitate the timely delivery of life-saving and timely support to people living in the most fragile and vulnerable environments...
**Institut Pasteur**  [to 10 Dec 2022]
Press Documents
No new digest content identified.

**ISC / International Science Council**  [to 10 Dec 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Current
Press releases
The International Science Council and Future Africa sign new agreement to co-design the ISC’s presence in Africa
08.12.2022

News
ISC appoints new Fellows to support its mission to bring science to society
05.12.2022
...The second cohort of Fellows includes eminent social and natural scientists, engineers and thought-leaders who have made impactful contributions in the science-policy sphere. They hail from different countries and regions, disciplines, sectors and career stages; having been nominated by ISC Members, Governing Board and Fellowship Council members, and sister networks like the Global Young Academy and InterAcademy Partnership. The three outgoing ISC patrons – Mary Robinson, Ismail Serageldin and Vint Cerf – have been awarded Honorary Fellowship status, in special recognition of their outstanding support to ISC...

News
Statement by international science advisors in advance of COP 15
05.12.2022

**International Union of Immunological Societies (IUIS)**
https://iuis.org/
News/Events [Selected]
No new digest content identified.

**IVAC**  [to 10 Dec 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

**IVI**  [to 10 Dec 2022]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 10 Dec 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News [Selected]
Center Faculty Contribute to Commentary Published in *Science* About Strengthening Oversight of Research Involving Enhanced Potential Pandemic Pathogens
December 8, 2022

MSF/Médecins Sans Frontières [to 10 Dec 2022]
http://www.msf.org/
Latest [Selected Announcements]
Afghanistan
People with tuberculosis face multiple barriers accessing treatment in Afghanistan
Project Update 8 Dec 2022

National Academy of Medicine - USA [to 10 Dec 2022]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 10 Dec 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 10 Dec 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 10 Dec 2022]
http://www.nih.gov/
News Releases
No new digest content identified.

PATH [to 10 Dec 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.
**Rockefeller Foundation** [to 10 Dec 2022]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
Dec 07 2022  Press Releases

**Building Stronger Pandemic Preparedness With Infectious Disease Modelling**

Nonthaburi, Thailand | November 25, 2022 – The Health Intervention and Technology Assessment Program (HITAP) announced the completion of the first Technical Workshop on Infectious Disease Modelling. Research staff from ...  

Dec 07 2022  Press Releases

**The Rockefeller Foundation and Digital Square at PATH Commit $5M to Strengthening Data-Driven Health Systems & Global Immunizations**

Two-year partnership will support deployment of digital tools and data analytics in Jamaica, Mali, Tanzania, Thailand, Uganda, and Zambia  

NEW YORK | December 7, 2022 – The Rockefeller Foundation and …

---

**Sabin Vaccine Institute** [to 10 Dec 2022]
https://www.sabin.org/press/
Latest News & Press Releases
Press Releases

**Sabin Vaccine Institute Delivers Ebola Sudan Vaccine to Fight Outbreak in Uganda**
December 8, 2022

Press Releases

**Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin’s Gold Medal and Rising Star Respectively**
December 7, 2022

---

**UNAIDS** [to 10 Dec 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
Press statement

**International Human Rights Day: ending the AIDS pandemic means respecting human rights for all**
GENEVA, 10 December 2022

---

**UNICEF** [to 10 Dec 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements  [Selected]
Press release 05 December 2022

**UNICEF appeals for US$10.3 billion emergency funding to support children affected by conflict, catastrophe and climate crises around the world**
GENEVA/NEW YORK, 5 December 2022 – UNICEF today launched a US$10.3 billion emergency funding appeal to reach more than 173 million people – including 110 million children – affected by humanitarian crises, the enduring effects of the COVID-19 pandemic worldwide and the growing threat of climate-impacted severe weather events. “Today, there are...

**Unitaid** [to 10 Dec 2022]
https://unitaid.org/
*Featured News*
09 December 2022
*A record 45 million children accessed seasonal malaria chemoprevention in 2021 thanks to Unitaid’s pioneering investments*

06 December 2022
*Executive Board approves Unitaid’s urgent action to confront antimalarial drug resistance in high burden areas*

**Vaccine Equity Cooperative [nee Initiative]** [to 10 Dec 2022]
https://vaccineequitycooperative.org/news/
*News*
*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 10 Dec 2022]
https://www.vaccineacceptance.org/
*Announcements, Blog*
*No new digest content identified.*

**Vaccine Confidence Project** [to 10 Dec 2022]
http://www.vaccineconfidence.org/
*News, Research and Reports*
*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 10 Dec 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
*News*
*No new digest content identified.*

**Wellcome Trust** [to 10 Dec 2022]
https://wellcome.ac.uk/news
*News, Opinion, Reports*
*No new digest content identified.*
The Wistar Institute  [to 10 Dec 2022]
Media
No new digest content identified.

WFPHA: World Federation of Public Health Associations  [to 10 Dec 2022]
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.

World Medical Association [WMA]  [to 10 Dec 2022]
Press Releases
No new digest content identified.

World Organisation for Animal Health (OIE)  [to 10 Dec 2022]
https://www.oie.int/en/
Press Releases, Statements
No new digest content identified.

ARM [Alliance for Regenerative Medicine]  [to 10 Dec 2022]
Selected Press Releases
No new digest content identified.

BIO  [to 10 Dec 2022]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 10 Dec 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations  [to 10 Dec 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

**IFPMA**  [to 10 Dec 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications

*Pharmaceutical industry statement delivered at CBD COP 15 meeting regarding Digital Sequence Information and the need for special measures for pathogen sharing*
07 December 2022

*Pharma industry contributions to third meeting of the Intergovernmental Negotiating Body (INB)*
07 December 2022

*Impact of a waiver of intellectual property rights for COVID-19 therapeutics*
05 December 2022

**International Alliance of Patients’ Organizations – IAPO**  [to 10 Dec 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

**International Generic and Biosimilar Medicines Association [IGBA]**
https://www.igbamedicines.org/
News
IGBA joins the Fight the Fakes Alliance (December 2022)

**PhRMA**  [to 10 Dec 2022]
http://www.phrma.org/
Press Releases
No new digest content identified.

::::::

**Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements**

**AstraZeneca**
Press Releases - No new digest announcements identified

**Bharat Biotech**
Press Releases - No new digest announcements identified

**BioCubaFarma** – Cuba
Últimas Noticias - Website not responding at inquiry
Biological E
News - No new digest announcements identified

BioNTech
Press Releases
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
9 December 2022

8 December 2022

5 December 2022

Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinnagen
Recent News - No new digest announcements identified

 Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.

GSK
Press releases for media - No new digest announcements identified

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified
Medicago
*Media*  - No new digest announcements identified

Merck
*News releases* - No new digest announcements identified

Moderna
*Press Releases*
08 December, 2022
*Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age*

Nanogen
*News* - No new digest announcements identified

Novartis
*News* - No new digest announcements identified

Novavax
*Press Releases*
Dec 7, 2022
*Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents*

Pfizer
*Recent Press Releases*
12.08.2022
*Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years*

12.07.2022
*U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults*

12.06.2022
*Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease*
Agreement aims to advance discovery and development of novel papain-like protease (PLpro) inhibitors and potentially introduce a new class of oral antivirals in the fight against COVID-19

12.05.2022
*Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years*

R-Pharm
https://rpharm-us.com/index.php
*[No news or media page identified]*
Sanofi Pasteur

Press Releases -- No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPIBBP

News - No new digest announcements identified

Sinovac

Press Releases

SINOVAC's Hepatitis A Vaccine Healive® Launched in Indonesia
2022/11/29

SK Biosciences

Press Releases - No new digest announcements identified

Takeda

Newsroom

Takeda's QDENGA® (Denque Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
December 8, 2022

Valneva

Press Releases

December 5, 2022

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Vector State Research Centre of Viralology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media

Recombinant COVID-19 Vaccine - Coviccine Developed by WestVac Biopharma/West China Hospital of Sichuan University Approved for Emergency Use
2022-12-05

Recently, the Recombinant COVID-19 Vaccine (Sf9 cell) - Coviccine developed by WestVac Biopharma Co., Ltd./West China Hospital of Sichuan University was approved by the relevant state authorities for emergency use, contributing to the prevention and control of the COVID-19 in China and the rest of the world. This is also the first insect cell-expressed Recombinant COVID-19 Vaccine approved for emergency use in China.
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 4
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 12: E1107-1182
https://journalofethics.ama-assn.org/issue/stillness-and-solidarity

With Stillness and Solidarity
This issue considers stillness and solidarity as necessary to orientating oneself to health care practice and professionalism. These two are both actions and virtues, which enable students’ and clinicians’ transformation from bystanders to upstanders. Stillness is conceived herein as intentional discipline applied to creating deliberate, restorative spatial and temporal interruption from day-to-day demands in order to nourish the moral motivational generosity needed to care well for patients and to be good colleagues. Solidarity is conceived herein as requiring deliberate nourishing in health professions education and work environments, such that slowing down, a necessary precedent set of actions to becoming still, can be robustly achieved and engaged. This issue explores ways in which solidarity can be considered less as a set of political actions of single individuals and more as a collective organizational and professional capacity for responding with care to both our unique and common vulnerabilities.
American Journal of Infection Control
December 2022  Volume 50  Issue 12  p1281-1400
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
December 2022  Volume 63  Issue 6p  875-1064
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
December 2022  112(12)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Volume 107 (2022): Issue 5 (Nov 2022)
[Reviewed earlier]

Annals of Internal Medicine
November 2022  Volume 175, Issue 11
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 313  December 2022
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-_allocation.biomedcentral.com/
(Accessed 10 Dec 2022)
[No new digest content identified]

BMJ Global Health
November 2022 - Volume 7 - 11
https://gh.bmj.com/content/7/11
BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 10 Dec 2022)
The development and validation of a novel COVID19 stigma scale among healthcare workers (COVISS-HCWs)
Fear of coronavirus disease 2019 (COVID-19) and its complications may result in stigmatization of individuals who may carry the virus. This is of special concern to healthcare workers who tolerate additional p...
Authors: Hasan Nabil Al Houri, Abdullah Alhouri, Rand T. Akasheh, Christine E. S. Jovanovic, Heba Al-tarcheh, Douaa Mohammad Nazir Arrouk, Ahmad Nabil Alhouri, Marah Marrawi, Malik E. Juweid and Youssef Latifeh
Citation: BMC Health Services Research 2022 22:1481
Content type: Research Published on: 5 December 2022

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 10 Dec 2022)
Pneumococcal concentration and serotype distribution in preschool children with radiologically confirmed pneumonia compared to healthy controls prior to introduction of pneumococcal vaccination in Zanzibar: an observational study
The World Health Organization recommends pneumococcal vaccination (PCV) in the first year of life. We investigated pneumococcal serotypes in children with clinical or radiologically confirmed pneumonia and hea...
Authors: Kristina Elfving, Lucia Gonzales Strömberg, Shadi Geravandi, Maria Andersson, Marc Bachelard, Mwinyi Msellem, Delér Shakely, Birger Trollfors, Rickard Nordén, Andreas Mårtensson, Anders Björkman and Magnus Lindh
Citation: BMC Infectious Diseases 2022 22:925
Content type: Research Published on: 10 December 2

Effectiveness of seasonal influenza vaccine in elementary and middle schools: a 10-year follow-up investigation
Influenza spreads from schools to the rest of society. Thus, we conducted questionnaire surveys of influenza vaccination in elementary and middle schools in a district for 10 years to determine immunization ra...
Authors: Teruyuki Kajiume, Sumera Mukai, Nobutaka Toyota, Ikuo Kanazawa, Akiko Kato, Etsushi Akimoto and Toshio Shirakawa
Citation: BMC Infectious Diseases 2022 22:909
Content type: Research article Published on: 6 December 2022

Five consecutive epidemiological waves of COVID-19: a population-based cross-sectional study on characteristics, policies, and health outcome
This study was conducted with the intension of providing a more detailed view about the dynamics of COVID-19 pandemic. To this aim, characteristics, implemented public health measures, and health outcome of CO...
COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities
Kevin Bardosh, et al.

Abstract
In 2022, students at North American universities with third-dose COVID-19 vaccine mandates risk disenrolment if unvaccinated. To assess the appropriateness of booster mandates in this age group, we combine empirical risk-benefit assessment and ethical analysis. To prevent one COVID-19 hospitalisation over a 6-month period, we estimate that 31,207–42,836 young adults aged 18–29 years must receive a third mRNA vaccine. Booster mandates in young adults are expected to cause a net harm: per COVID-19 hospitalisation prevented, we anticipate at least 18.5 serious adverse events from mRNA vaccines, including 1.5–4.6 booster-associated myopericarditis cases in males (typically requiring hospitalisation). We also anticipate 1430–4626 cases of grade ≥3 reactogenicity interfering with daily activities (although typically not requiring hospitalisation). University booster mandates are unethical because they: (1) are not based on an updated (Omicron era) stratified risk-benefit assessment for this age group; (2) may result in a net harm to healthy young adults; (3) are not proportionate: expected harms are not outweighed by public health benefits given modest and transient effectiveness of vaccines against transmission; (4) violate the reciprocity principle because serious vaccine-related harms are not reliably compensated due to gaps in vaccine injury schemes; and (5) may result in wider social harms. We consider counterarguments including efforts to increase safety on campus but find these are fraught with limitations and little scientific support. Finally, we discuss the policy relevance of our analysis for primary series COVID-19 vaccine mandates.

Assent, parental consent and reconsent for health research in Africa: thematic analysis of national guidelines and lessons from the SickleInAfrica registry

The enrolment of children and adolescents in health research requires that attention to be paid to specific assent and consent requirements such as the age range for seeking assent; conditions for parental con...

Children as an afterthought during COVID-19: defining a child-inclusive ethical framework for pandemic policymaking

Following the SARS pandemic, jurisdictions around the world began developing ethical resource allocation frameworks for future pandemics—one such framework was developed by Thompson and colleagues. While this ...

AUTHORS: Rozhin Amin, Mohammad-Reza Sohrabi, Ali-Reza Zali and Khatereh Hannani
Citation: BMC Infectious Diseases 2022 22:906
Content type: Research Published on: 5 December 2022
Guardians and research staff experiences and views about the consent process in hospital-based paediatric research studies in urban Malawi: A qualitative study

Obtaining consent has become a standard way of respecting the patient’s rights and autonomy in clinical research. Ethical guidelines recommend that the child’s parent/s or authorised legal guardian provides in...

Authors: Mtisunge Joshua Gondwe, Neema Mtunthama Toto, Charity Gunda, Markus Gmeiner, Ian J. C. MacCormick, David Laloo, Michael Parker and Nicola Desmond

Citation: BMC Medical Ethics 2022 23:125

Content type: Research article Published on: 5 December 2022

BMC Medicine
http://www.biomedcentral.com/bmcmd/content
(Accessed 10 Dec 2022)
[No new digest content identified]

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 10 Dec 2022)
[No new digest content identified]

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 10 Dec 2022)

The influence of social class and institutional relationships on the experiences of vaccine-hesitant mothers: a qualitative study

Vaccine hesitancy is a growing problem in the United States. However, our understanding of the mechanisms by which socioeconomic status (SES) shapes the experience of vaccine hesitancy and decision-making is i...

Authors: Lindsay W. Glassman and Julia E. Szymczak

Citation: BMC Public Health 2022 22:2309

Content type: Research Published on: 9 December 2022

COVID-19 vaccination acceptance in underserved urban areas of Islamabad and Rawalpindi: results from a cross-sectional survey

Urban slums are home to a significant number of marginalized individuals and are often excluded from public services. This study explores the determinants of willingness and uptake of COVID-19 vaccines in urba...

Authors: Twangar Kazmi, Mujahid Abdullah, Adnan Ahmad Khan, Rana Muhammad Safdar, Sabeen Afzal and Ayesha Khan

Citation: BMC Public Health 2022 22:2299

Content type: Research Published on: 8 December 2022

Excess mortality and the COVID-19 pandemic: causes of death and social inequalities
During the coronavirus diseases 2019 (COVID-19) pandemic, population’s mortality has been affected not only by the risk of infection itself, but also through deferred care for other causes and changes in lifes...

Authors: Jieun Oh, Jieun Min, Cinoo Kang, Ejin Kim, Jung Pyo Lee, Ho Kim and Whanhee Lee
Citation: BMC Public Health 2022 22:2293
Content type: Research Published on: 7 December 2022

Knowledge of cervical cancer prevention and treatment, and willingness to receive HPV vaccination among college students in China
Cervical cancer is the fourth most common cancer in women. Up to 99% of cervical cancer cases are associated with high-risk human papillomavirus (HPV). Sexual behavior is a direct risk factor for HPV infection...

Authors: Fengzhi Zhang, Manman Li, Xiaoxue Li, Hua Bai, Jinling Gao and Hua Liu
Citation: BMC Public Health 2022 22:2269
Content type: Research Published on: 5 December 2022

Assessing barriers to access and equity for COVID-19 vaccination in the US
Historical vaccination coverage in economically disadvantaged, ethnic minority, non-affluent white and agricultural populations in the US has lagged coverage in more affluent urban and suburban white population...

Authors: Michael Kuehn, Joyce LaMori, Jessica K. DeMartino, Marco Mesa-Frias, Jason Doran, Lohit Korrapati, Rhea Bhojwani, Patrick Lefebvre and Noam Kirson
Citation: BMC Public Health 2022 22:2263
Content type: Research Published on: 3 December 2022

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 10 Dec 2022)
[No new digest content identified]

BMJ Evidence-Based Medicine
December 2022 - Volume 27 - 6
https://ebm.bmj.com/content/27/6
[Reviewed earlier]

BMJ Open
November 2022 - Volume 12 - 11
https://bmjopen.bmj.com/content/12/11
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 100(12); 2022 Dec 1
https://www.ncbi.nlm.nih.gov/pmc/issues/422466/
[Reviewed earlier]
Featured Article

**Immune cell interactions in tuberculosis**
JoAnne L. Flynn, John Chan

Tuberculosis is an infectious disease affecting millions worldwide. The causative pathogen, *Mycobacterium tuberculosis* deploys multiple mechanisms to evade host immune responses, thus challenging the development of an effective vaccine. This review highlights the importance of understanding immune cells in tuberculosis in a holistic manner to better achieve protective immunity.

---

**Child Care, Health and Development**
Volume 48, Issue 6: Pages 881-1137  November 2022

**Special Issue: The Pervasive Effects of COVID-19 on Children: A Global Perspective**
Issue Edited by: Jan Willian Gorter, Evelyn Culnane, Lyndal Hickey, Mark Ferro, Tony Okely
[Reviewed earlier]

---

**Clinical Pharmacology & Therapeutics**
Volume 112, Issue 6: Pages 1131-1339  December 2022

**Editorial  Free Access**

**How a Pandemic Simultaneously Strengthened Existing Fundamentals and Drove New Innovations in Clinical Pharmacology**
Shirley K. Seo, Piet H. van der Graaf
Pages: 1141-1144
First Published: 19 November 2022

**Reviews  Open Access**

**The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making**
Elodie Baumfeld Andre, Nate Carrington, Flora S. Siami, Jo Carol Hiatt, Carly McWilliams, Carolyn Hiller, Andy Surinach, Alejandro Zamorano, Chris L. Pashos, Wade L. Schulz
Pages: 1172-1182
First Published: 25 February 2022

**Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV-2**
Pages: 1224-1235
First Published: 19 August 2022
Patient Recruitment  Abstract only
Using plain language to communicate with clinical trials participants: Comparison of readability calculators
Lauren McGrath, Beverley C. Millar, John E. Moore
Article 106995

Abstract

It is important that patient-facing clinical trial information is easily understood by potential trial participants, active trial participants, family members, friends and carers. The readability of a document refers to its typographic and linguistic characteristics that allow the text to be read and comprehended and it is recommended that healthcare providers aim that all information disseminated to the lay public be at a suitable readability level. Whilst there are established readability calculators for literature, there is no standard for health information. Several readability calculators are available that aid in the analysis of a text, URL or website's readability, however, to date there has been no head-to-head comparison of these. Five readability calculators were compared, including four online realtime calculators, (i) Readable (www.readable.com), (ii) www.webfx.com, (iii) www.datayze.com and (iv) www.online-utility.org, as well as the PC-based analyzer Microsoft Word (Microsoft Corp., USA). Three categories of text information were analysed, including (i) children's fairy tales (n = 20) (ii) scientific reports (n = 20) from BBC News websites and (iii) scientific abstracts (n = 20). This study demonstrated that varying scores were obtained by using different readability calculators. Based on these data in combination with issues including availability and ease-of-use, we advocate the use of Readable or Microsoft Word software to aid in the preparation of patient-facing clinical trial information. Clinical trial networks should now consider the need for standardisation of readability calculators and provide guidance to stakeholders so that readability of materials may be improved in a standardised and uniform manner.
The CRISPR Journal
Volume 5, Issue 5 / October 2022
https://www.liebertpub.com/toc/crispr/5/5
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 10, issue 3, September 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-3
[Reviewed earlier]

Current Opinion in Infectious Diseases
December 2022 - Volume 35 - Issue 6
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 4 Pages: 181-299 December 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 8, 2022
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 5 - October 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 1 Pages: 1-244 January 2023
https://onlinelibrary.wiley.com/toc/14677717/current
Opinion
14 November 2022  Free to Read
Scholars in peril: when being a scientist can land you in jail (or worse)
Shina Caroline Lynn Kamerlin
The scientific community needs to speak up loudly to support colleagues who are persecuted and imprisoned for political reasons.

Emerging Infectious Diseases
Volume 28, Number 12—December 2022
http://wwwnc.cdc.gov/eid/
Synopses
Probable Aerosol Transmission of SARS-CoV-2 through Floors and Walls of Quarantine Hotel, Taiwan, 2021 [PDF - 2.81 MB - 9 pages]
H. Wei et al.

Research
Association between Conflict and Cholera in Nigeria and the Democratic Republic of the Congo [PDF - 3.77 MB - 10 pages]
G. Charnley et al.

Epidemics
Volume 41  December 2022
https://www.sciencedirect.com/journal/epidemics/vol/41/suppl/C
Research article  Open access
The role of public involvement in the design of the first SARS-CoV-2 human challenge study during an evolving pandemic
Maria Piggin, Emma Smith, Peter Mankone, Leah Ndegwa, ... Caroline Barker
Article 100626
Highlights
• Public involvement informed the design of a SARS-CoV-2 human challenge study.
• Discussions supported decision making around study exclusion criteria.
• Study materials and consent processes were changed following public review.
• The public were concerned for the wellbeing of participants.
• Human challenge studies were seen as efficient and fast.
• Public insights supported ethical review of the study.

Research article  Open access
Impact of disruptions to routine vaccination programs, quantifying burden of measles, and mapping targeted supplementary immunization activities
Natalya Kostandova, Stacie Loisate, Amy Winter, William J. Moss, ... Amy Wesolowski
Article 100647
**Research article  Open access**

**Considering equity in priority setting using transmission models: Recommendations and data needs**

M. Quaife, GF Medley, M. Jit, T. Drake, ... GB Gomez

Article 100648

**Research article  Open access**

**In the shadow of privacy: Overlooked ethical concerns in COVID-19 digital epidemiology**

Agata Ferretti, Effy Vayena

Article 100652

**Highlights**

- Digital epidemiology holds great potential to surveil and fight epidemics.
- Privacy monopolizes the debate on the ethics and governance of digital epidemiology.
- Other important issues and their ethical consequences remain unaddressed.
- Overlooking these issues will undermine the power of health surveillance technology.
- Need for a broader ethical approach and a social license for data uses.

**Epidemiology and Infection**

Volume 150 - 2022

https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue

[Reviewed earlier]

**Ethics & Human Research**

Volume 44, Issue 6  Pages: 1-42  November–December 2022

https://onlinelibrary.wiley.com/toc/25782363/current

Alzheimer disease biomarkers :: Payment to participate

[Reviewed earlier]

**Ethics & International Affairs**

Summer 2022 (36.2) | July 29, 2022


**ROUNDTABLE: VULNERABLE COMMUNITIES, FUTURE GENERATIONS, AND POLITICAL REPRESENTATION IN CLIMATE POLICY AND PRACTICE**

... This roundtable collection is motivated by the following question: How can the voices of vulnerable communities and future generations be adequately and fairly represented within climate change policy and practice? The contributions address this question from several perspectives. Simon Caney focuses on global governance institutions to protect the interests of future generations, considering specific proposals and asking what criteria should be used to evaluate them. Stephen Gardiner’s essay builds on his previous work calling for a global constitutional convention, elaborating on the proposal and addressing objections to it. Colin Hickey argues that it is necessary to consider more informal modes of representing vulnerable communities and future generations, such as through grassroots organizations. In our contribution, we argue that the interests of future generations are best represented in deliberations around climate policy and practice by those already most vulnerable to the impacts of climate change. Marco Grix and Krushil Watene’s essay argues that the representation of climate-
vulnerable communities and future generations—in particular, Indigenous peoples—must ensure the protection of the complex network of social practices that guide how vulnerable communities respond to climate change...

**Ethics, Medicine and Public Health**
Volume 25  December 2022

*Editorial*
**Praise of a medical and public health ethics for the 21st century**
C. Herve, P. Charlier
Article 100286

**Beyond Covid-19, why AI is revolutionizing the scientific ecosystem**
C. Bommier, J. Haiech, P. Charlier, DALL-E2, DaVinci-002
Article 100853

**The European Journal of Public Health**
Volume 32, Issue 6, December 2022
https://academic.oup.com/eurpub/issue/32/6

*Editorials*
‘**Disease X**’—time to act now and prepare for the next pandemic threat
Daniele Mipatrini, Chiara Montaldo, Barbara Bartolini, Giovanni Rezza, Sergio Iavicoli ...

**Covid-19**
**Media use and trust during the COVID-19 pandemic: evidence from eight cross-sectional surveys in Sweden**
Maike Winters, Olivia Biermann, Gustav Bohlin, Martin Bergman, Fredrik Brounéus ...
European Journal of Public Health, Volume 32, Issue 6, December 2022, Pages 976–981,

**Electoral and religious correlates of COVID-19 vaccination rates in Dutch municipalities**
Alexandre Afonso, Fabio Votta
https://doi.org/10.1093/eurpub/ckac112

**Expert Review of** Vaccines
Vol 21 (12) 2022
https://www.tandfonline.com/toc/ierv20/current

*Editorial*
**Influence of social media on the public perspectives of the safety of COVID-19 vaccines**
Sai Krishna Gudi, Sophia M. George & Jimmy Jose
Pages: 1697-1699
Published online: 12 Apr 2022

*Article*
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative

Javier Díez-Domingo, Laurence Torcel-Pagnon, Antonio Carmona, Odile Launay, Gaël Dos Santos, Caterina Rizzo, Mendel Haag, Anke Stuurman, Jos Nauta, Alfredo Vannacci, Simon de Lusignan, Elena Del Rey, Miriam Levi, Bruno Lina, Stefania Bellino, Samantha Nye, Pieter Neels, Hanna Nohynek & Cédric Mahéon behalf of the DRIVE consortium

Pages: 1701-1710
Published online: 27 Oct 2022

Review

Modern vaccine strategies for emerging zoonotic viruses

Atif Ahmed, Muhammad Safdar, Samran Sardar, Sahar Yousaf, Fiza Farooq, Ali Raza, Muhammad Shahid, Kausar Malik & Samia Afzal

Pages: 1711-1725
Published online: 27 Nov 2022

Review

Success of nano-vaccines against COVID-19: a transformation in nanomedicine

Manoj Kumar Sarangi, Sasmita Padhi, Gautam Rath, Sitansu Sekhar Nanda & Dong Kee Yi

Pages: 1739-1761
Published online: 27 Nov 2022

Review

Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review

Wei (Vivian) Wang, Smita Kothari, Jozica Skufca, Anna R. Giuliano, Karin Sundström, Mari Nygård, Carol Koro, Marc Baay, Thomas Verstraeten, Alain Luxembourg, Alfred J. Saah & Suzanne M. Garland

Pages: 1799-1817
Published online: 04 Nov 2022

Meta-analysis

Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis

Angela Meggiolaro, Monica Sane Schepisi, Sara Farina, Carolina Castagna, Alessia Mammano, Andrea Siddu, Paola Stefanelli, Stefania Boccia & Giovanni Rezza

Pages: 1831-1841
Published online: 14 Oct 2022

Article

The impact of vaccination on the burden of invasive pneumococcal disease from a nationwide surveillance program in Lebanon: an unexpected increase in mortality driven by non-vaccine serotypes

Mohamad El-Zaatari, Elie Salem Sokhn, Nada Ghosn, Walid Ammar, Randa Hamadeh, Ghassan M. Matar, George F. Araj & Ghassan S. Dbaibo for the Lebanese Inter-Hospital Pneumococcal Surveillance Program investigators
Pages: 1905-1921
Published online: 17 Nov 2022

Foreign Affairs
Volume 101, Number 6  November/December 2022
https://www.foreignaffairs.com/issues/2022/101/6
[New issue; No digest content identified]

Forum for Development Studies
Volume 49, 2022 - Issue 3
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genetics in Medicines
Volume 24, Issue 12  Pages A1-A8, 2419-2598 (December 2022)
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/24/issue/12
Research article  Open access
Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020
Jessica C. Tiner, Leah E. Mechanic, Lisa Gallicchio, Elizabeth M. Gillanders, Kathy J. Helzlsouer
Pages 2526-2534

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 10 Dec 2022]
[No new digest content identified]

Global Health Action
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
Vol. 10, No. 5  October 31, 2022
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
Bridging the genomic data gap in Africa: implications for global disease burdens

This paper highlights the gap in the use of genomic data of Africans for global research efforts for disease cures. Genomic data represents an important tool used in disease research for understanding how dise...

Authors: Olabode Ebenezer Omotoso, John Oluwafemi Teibo, Festus Adebayo Atiba, Tolulope Oladimeji, Ayomide Oluwadarasimi Adebesin and Ahmad O. Babalghith

Citation: Globalization and Health 2022 18:103
Content type: Review Published on: 9 December 2022
Human Gene Therapy
Volume 33, Issue 21-22 / November 2022
https://www.liebertpub.com/toc/hum/33/21-22
[Reviewed earlier]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

Immunity
Nov 08, 2022 Volume 55 Issue 11 p1967-2210
https://www.cell.com/immunity/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 10 Dec 2022]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 10 Dec 2022]
[No new digest content identified]

International Health
Volume 14, Issue 6, November 2022
https://academic.oup.com/inthealth/issue/14/6
[Reviewed earlier]

International Human Rights Law Review
Volume 11 (2022): Issue 1 (Jun 2022)
https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml
Table of Contents
[Reviewed earlier]
JAMA Pediatrics
December 2022, Vol 176, No. 12, Pages 1160-1276
https://jamanetwork.com/journals/jamapediatrics/currentissue

Original Investigation
Effect of Wearing a Face Mask on Hand-to-Face Contact by Children in a Simulated School EnvironmentThe Back-to-School COVID-19 Simulation Randomized Clinical Trial
Michelle Science, MD, MSc; Monica Caldeira-Kulbakas, PhD; Rulan S. Parekh, MD, MSc, FRCP; et al.
open access has active quiz

This randomized clinical trial evaluates the effect of wearing a face mask on hand-to-face contact by children while at school.

Special Communication
Reimagining Children’s Rights in the US
Elizabeth Barnert, MD, MPH, MS; Joseph Wright, MPH, MS; Charlene Choi, JD; et al.
has active quiz

This Special Communication discusses the potential ways in which the US can advance children’s rights through the adoption of a children’s rights framework and the implementation of a children’s rights approach to benefit and protect children’s health and well-being.

Importance The US faces a pivotal moment of opportunity and risk regarding issues affecting children (aged 0-17 years). Although the US remains the only United Nations member state to not have
ratified the Convention on the Rights of the Child (CRC), a child rights framework is essential for child health professionals seeking to advance many issues affecting children in the US. The Reimagining Children’s Rights project (2020-2021) conducted an in-depth environmental scan of relevant literature and policy analysis using the Three Horizons design process to assess strategies that could advance the rights and well-being of children in the US. The project was overseen by a steering committee and informed by an advisory committee composed of youth leaders and experts in children’s rights, advocacy, health, law, and a range of child-specific issues (eg, youth justice, early childhood development), who provided expert input on strategic considerations for advancing children’s rights.

**JBI Evidence Synthesis**  
November 2022 - Volume 20 - Issue 11  
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx  
[Reviewed earlier]

**Journal of Adolescent Health**  
December 2022 Volume 71 Issue 6 p655-772  
https://www.jahonline.org/current  
*Original Articles*  
*Parents’ Acceptance of COVID-19 Compared to Human Papillomavirus Vaccines*  
Alison Footman, et al.  
Published online: October 05, 2022  
p673-678

**Journal of Artificial Intelligence Research**  
Vol. 75 (2022)  
https://www.jair.org/index.php/jair  
*Contents*  
[Reviewed earlier]

**Journal of Community Health**  
Volume 47, issue 6, December 2022  
https://link.springer.com/journal/10900/volumes-and-issues/47-6  
[Reviewed earlier]

**Journal of Development Economics**  
Volume 160 January 2023  
[New issue; No digest content identified]

**Journal of Empirical Research on Human Research Ethics**  
Volume 17 Issue 5, December 2022  
http://journals.sagepub.com/toc/jre/current
Ethical Issues using Digital Surveillance Technologies in Research
[Reviewed earlier]

Journal of Epidemiology & Community Health
December 2022 - Volume 76 - 12
https://jech.bmj.com/content/76/12
Commentaries
Global inequity of COVID-19 diagnostics: challenges and opportunities (6 October, 2022)
Shanti Narayanasamy, Brenda Okware, Winters Muttamba, Kirtika Patel, Kwabena Obeng Duedu, Nirmal Ravi, Nathan Ellermeier, Muki Shey, Christopher W Woods, Wilber Sabiiti

Journal of Evidence-Based Medicine
Volume 15, Issue 3  Pages: 181-314  September 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 18, Issue 2, 2022
http://www.tandfonline.com/toc/rjge20/current
Symposium
Article
A neo-feudal world order? Introduction to the symposium on Peter Hägel’s Billionaires in World Politics
Julian Culp
Pages: 196-200
Published online: 29 Nov 2022

Research Article
Billionaires in world politics: donors, governors, authorities
Klaus Dingwerth & Julian Eckl
Pages: 201-210
Published online: 29 Nov 2022

Article
The democratic deficit of the G20
Sören Hilbrich
Pages: 248-266
Published online: 10 Oct 2021

Article
The right to immigrate and responsibility for the past
Michael Rabinder James
Pages: 267-285
Published online: 17 Jun 2022
Table of Contents

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 4, November 2022
https://muse.jhu.edu/issue/48371
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 24, issue 6, December 2022
https://link.springer.com/journal/10903/volumes-and-issues/24-6
Contents
The Impact of a Comic Book Intervention on East African-American Adolescents’ HPV Vaccine-Related Knowledge, Beliefs and Intentions
Authors (first, second and last of 12)
Michelle B. Shin, et al.
Content type: Original Paper
Published: 31 March 2022
Pages: 1489 - 1500

Journal of Immigrant & Refugee Studies
Volume 20, 2022, Issue 4
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 226, Issue 10, 15 November 2022
https://academic.oup.com/jid/issue/226/10
[Reviewed earlier]

Journal of International Development
Volume 34, Issue 8 Pages: 1453-1648 November 2022
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Medical Ethics
December 2022 - Volume 48 - 12
http://jme.bmj.com/content/current
Current controversies
Vaccine passports and health disparities: a perilous journey (9 July, 2021) Free
Nancy S Jecker

Original research
Public attitudes about equitable COVID-19 vaccine allocation: a randomised experiment of race-based versus novel place-based frames (4 August, 2022)
Harald Schmidt, Sonia Jawaid Shaikh, Emily Sadecki, Alison Buttenheim, Sarah Gollust

Accessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of ‘compassionate therapies’ in times of catastrophic pandemics (13 October, 2021) Free
Shlomit Zuckerman, Yaron Barlavie, Yaron Niv, Dana Arad, Shaul Lev

How low can you go? Justified hesitancy and the ethics of childhood vaccination against COVID-19 (25 February, 2022)
Stephen David John

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 3 (2022)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
November 2022 Volume 250 p1-118
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 10 Dec 2022]
[No new digest content identified]

Journal of Public Health Management & Practice
November/December 2022 - Volume 28 - Issue 6
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 43, issue 3, September 2022
https://link.springer.com/journal/41271/volumes-and-issues/43-3
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]
**Journal of the Royal Society – Interface**
December 2022  Volume 19  Issue 197  
https://royalsocietypublishing.org/toc/rsif/current  
[New issue; No digest content identified]

**Journal of Travel Medicine**
Volume 29, Issue 7, October 2022  
https://academic.oup.com/jtm/issue  
[Reviewed earlier]

**Journal of Virology**
Volume 96  Number 18  September 2022  
http://jvi.asm.org/content/current  
[Reviewed earlier]

**The Lancet**
Dec 10, 2022  Volume 400  Number 10368  p2007-2154, e13  
https://www.thelancet.com/journals/lancet/issue/current  

*Editorial*

**Advancing racial and ethnic equity in health**
The Lancet

*Series*

**Racism, Xenophobia, Discrimination, and Health**

*Executive summary*
Delan Devakumar, et al.

**Racism, xenophobia, discrimination, and the determination of health**
Delan Devakumar, et al.

**Racism, xenophobia, and discrimination: mapping pathways to health outcomes**
Sujitha Selvarajah, et al.

**Intersectional insights into racism and health: not just a question of identity**
Geordan Shannon, et al.

**Confronting the consequences of racism, xenophobia, and discrimination on health and health-care systems**
Ibrahim Abubakar, et al.

**The Lancet Child & Adolescent Health**
Dec 2022  Volume 6  Number 12  p829-894, e24-e28  
https://www.thelancet.com/journals/lanchi/issue/current
Comment

**Ethical artificial intelligence in paediatrics**
Samantha Boch, Emre Sezgin, Simon Lin Linwood

The use of artificial intelligence (AI) in paediatric research and clinical practice has steadily increased and has mostly been leveraged to augment diagnostic assessment, risk prediction, and treatment of specific child health conditions.1 Yet, AI efforts focused on health equity are limited to the adult population2 or early-life adversities due to environmental exposures.3 In paediatrics, AI could aid providers and systems in understanding and mitigating social risk, and nurturing more equitable care.4

Lancet Digital Health
Dec 2022 Volume 4 Number 12 e850-e905
https://www.thelancet.com/journals/landig/issue/current
[New issue; No digest content identified]

Lancet Global Health
Dec 2022 Volume 10 Number 12 e1688-e1866
https://www.thelancet.com/journals/langlo/issue/current
Comment

**Seasonal targeting of the RTS,S/AS01 malaria vaccine: a complementary tool but sustained funding is required**
Sheetal Prakash Silal

**Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame**
Kimberly M Thompson

Articles

**Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019**
GBD 2019 Healthcare Access and Quality Collaborators

**Global impact of COVID-19 on childhood tuberculosis: an analysis of notification data**
Lasith Ranasinghe, et al.

**Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study**
Hayley A Thompson, et al.

Viewpoint

**Ethics and governance challenges related to genomic data sharing in southern Africa: the case of SARS-CoV-2**
Keymanthri Moodley, et al.

Lancet Infectious Diseases
Dec 2022 Volume 22 Number 12 p1649-1770, e348-e381
Editorial
Why hybrid immunity is so triggering
The Lancet Infectious Diseases

Comment
Evaluating novel COVID-19 vaccines in the current chapter of the pandemic
Corine H GeurtsvanKessel, Rory D de Vries

Articles
Karin Hardt, et al. for the ENSEMBLE2 study group

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial
Rajeka Lazarus, et al. on behalf of the Valneva phase 3 trial group

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years’ follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
Mehreen S Datoo, et al.

Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study
Todd D Swarthout, et al.

Review
Prevention of monkeypox with vaccines: a rapid review
Gregory A Poland, Richard B Kennedy, Pritish K Tosh

Personal View
The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned
Ensheng Dong, et al.

Lancet Public Health
Dec 2022 Volume 7 Number 12 e983-e1090
https://www.thelancet.com/journals/lanpub/issue/current
Editorial
The fate of public health in China
The Lancet Public Health

Health Policy
Developing an effective and sustainable national immunisation programme in China: issues and challenges
Shu Chen, et al.

**Lancet Respiratory Medicine**
Dec 2022 Volume 10 Number 12 p1099-1188, e107-e116
https://www.thelancet.com/journals/lanres/issue/current
[New issue; No digest content identified]

**Maternal and Child Health Journal**
Volume 26, issue 11, November 2022
[Reviewed earlier]

**Medical Decision Making (MDM)**
Volume 43 Issue 1, January 2023
http://mdm.sagepub.com/content/current
[New issue; No digest content identified]

**The Milbank Quarterly**
A Multidisciplinary Journal of Population Health and Health Policy
Volume 100, Issue 3 Pages: 617-961 September 2022
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

**Nature**
Volume 612 Issue 7939, 8 December 2022
https://www.nature.com/nature/volumes/612/issues/7939
[New issue; No digest content identified]

**Nature Biotechnology**
Volume 40 Issue 11, November 2022
https://www.nature.com/nbt/volumes/40/issues/11
News 08 Nov 2022
For hemophilia and thalassemia, a new era of ‘one-and-done’ gene therapies has arrived
Industry celebrates two newly approved genetic medicines, but patients with these blood disorders may face a long wait, and many will never access them because of their high cost.
Cormac Sheridan

Review Article 03 Nov 2022
Unlocking the promise of mRNA therapeutics
mRNA therapeutics face more challenges than mRNA vaccines, but solutions are on the horizon.
Genetic futurism

Large-scale genotyping and phenotyping efforts, including biobanks, have revolutionized our understanding of the genetic architecture of human traits and diseases. Years of ever-larger genome-wide association studies (GWAS) have produced a catalog of genetic variants that contribute to complex traits. A corollary of this research has been the development of personalized polygenic scores (PGS) or polygenic risk scores (PRS).

Comment 29 Nov 2022

Mapping the Arab genome

The Qatar Genome Program was established to interrogate the genomics and genetics of populations in the Middle East. Improving precision medicine strategies and building long-term research capacity are both key aims of the initiative.
Hamdi Mbarek, Said I. Ismail

Nature Human Behaviour
Volume 6 Issue 11, November 2022
https://www.nature.com/nathumbehav/volumes/6/issues/11
[Reviewed earlier]

Nature Medicine
Volume 28 Issue 11, November 2022
https://www.nature.com/nm/volumes/28/issues/11
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 21 Issue 12, December 2022
https://www.nature.com/nrd/volumes/21/issues/12
Comment 17 Oct 2022

The NCATS Assay Guidance Manual programme: advancing the practice and rigour of preclinical translation

The Assay Guidance Manual programme, a translational science education and training initiative at the US National Center for Advancing Translational Sciences (NCATS), aims to help bridge the gap
between research discoveries and the delivery of new therapies by creating and disseminating experimental protocols and standards for rigour in preclinical translational research.

Sarine Markossian, Kyle R. Brimacombe, Matthew D. Hall

*An Audience With* 11 Nov 2022

**COVID vaccines: “We flew the aeroplane while we were still building it”**

Recently retired head of vaccine R&D at Pfizer, Kathrin Jansen, discusses the lightning speed development of SARS-CoV-2 vaccines — and the implications for vaccine platforms.

Katie Kingwell

**Nature Reviews Genetics**

Volume 23 Issue 12, December 2022

https://www.nature.com/nrg/volumes/23/issues/12

[New issue; No digest content identified]

**Nature Reviews Immunology**

Volume 22 Issue 12, December 2022

https://www.nature.com/nri/volumes/22/issues/12

*Comment* 25 Oct 2022

**Principles of disease defence in organisms, superorganisms and societies**

Social insects such as ants form a superorganism in which individual colony members cooperate for disease defence, much like the cells of an organism. Studying social insect colonies can help to determine common principles that unite the disease defences of organisms, superorganisms and societies.

Sylvia Cremer, Michael Sixt

**New England Journal of Medicine**

December 8, 2022  Vol. 387 No. 23

https://www.nejm.org/toc/nejm/medical-journal

*Editorials*

**Audio Interview: Covid-19 and Health Equity**

E.J. Rubin, L.R. Baden, M. Hlatshwayo Davis, and S. Morrissey

**npj Vaccines**

https://www.nature.com/npjvaccines/

[Accessed 10 Dec 2022]

[No new digest content identified]

**Pediatrics**

Volume 150, Issue 5  November 2022

https://publications.aap.org/pediatrics/issue/150/5

*Articles*

[Reviewed earlier]
PharmacoEconomics
Volume 40, issue 12, December 2022
https://link.springer.com/journal/40273/volumes-and-issues/40-12
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 10 Dec 2022)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 10 Dec 2022)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 10 Dec 2022)
[No new digest content identified]

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 10 Dec 2022)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 10 Dec 2022]
Research Article
Frameworks for mitigating the risk of waterborne diarrheal diseases: A scoping review
Chisala D. Meki, Esper J. Ncube, Kuku Voyi
Research Article | published 09 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0278184

Rural parents’ attitudes and beliefs on the COVID-19 pediatric vaccine: An explanatory study
Rachael Lacy, Jini Puma, Michael Tubolino, David LaRocca, Lori A. Crane, Lisa Miller, Chad D. Morris, Sean T. O'Leary, Jenn A. Leiferman
Research Article | published 07 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0278611
Self-correction in science: The effect of retraction on the frequency of citations
Anton Kühberger, Daniel Streit, Thomas Scherndl
Research Article | published 07 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0277814

Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies
Megan Wallace, Jennifer P. Collins, Heidi Moline, Ian D. Plumb, Monica Godfrey, Rebecca L. Morgan, Doug Campos-Outcalt, Sara E. Oliver, Kathleen Dooling, Julia W. Gargano
Research Article | published 06 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0278624

Beliefs regarding COVID-19 vaccinations of young adults in the United Kingdom: An interview study applying the Integrated Change Model
Ilja van Bergen, Sophie Böger, Charlotte Beaudart, Mickaël Hiligsmann, Kei Long Cheung
Research Article | published 06 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0277109

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 10 Dec 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
December 13, 2022 vol. 119 no. 50
https://www.pnas.org/toc/pnas/119/50
[New issue; No digest content identified]

Prehospital & Disaster Medicine
Volume 37 - Supplement S2 - November 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
Abstracts of World Health Organization Emergency Medical Teams Global Meeting 2022

Preventive Medicine
Volume 164 November 2022
[Reviewed earlier]

Proceedings of the Royal Society B
07 December 2022 Volume 289 Issue 1988
https://royalsocietypublishing.org/toc/ rspb/current
[New issue; No digest content identified]
Smallpox vaccination and vaccine hesitancy in the Kingdom of the Two Sicilies (1801) and the great modernity of Ferdinand IV of Bourbon: a glimpse of the past in the era of the SARS-COV-2 (COVID-19) pandemic
M. Martini, M. Bifulco, D. Orsini
Pages 47-53

Features of human papillomavirus vaccination education strategies in low- and middle-income countries: a scoping review
E.A. Marfo, K.D. King, C.A. Adjei, S.E. MacDonald
Pages 61-67

Public Health Ethics
Volume 15, Issue 1, April 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 6, November/December 2022
https://journals.sagepub.com/toc/phrg/137/6
[Reviewed earlier]

Qualitative Health Research
Volume 32 Issue 14, December 2022
https://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]

Research Ethics
Volume 18 Issue 4, October 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 10 Dec 2022]
[No new digest content identified]
Selected Content

Discussion

**Moral injury in health care: A focus on immunization**
Rosemary Ricciardelli, Noni E. MacDonald
Pages 7011-7013

Research article  Abstract only

**Opinions, attitudes, and barriers to pediatric vaccination in Argentina**
A. Urueña, J.I. Ruiz, D.A. Lew, J. David, ... C. Vizzotti
Pages 7042-7049

Research article  Abstract only

**Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly**
Shu-ling Hoshi, Aiko Shono, Xerxes Seposo, Reiko Okubo, Masahide Kondo
Pages 7057-7064

Research article  Open access

**Developing communication tools on rotavirus vaccination to support family paediatricians in Italy**
Federico Marchetti, Giulia Lamiani, Marco Bona, Chiara Amerighi, ... Giorgio Conforti
Pages 7108-7114

Research article  Full text access

**The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study**
Weike Zhou, Biao Tang, Yao Bai, Yiming Shao, ... Sanyi Tang
Pages 7141-7150

Research article  Full text access

**Identifying early adopters of COVID-19 vaccines in Latin America**
Alejandro Arrieta, Ariadna García-Prado, Juan Pablo Sarmiento, Carmen Paz Castro
Pages 7158-7166

Vaccines

https://www.mdpi.com/journal/vaccines
[Accessed 10 Dec 2022]

Latest Articles

Open Access  Article

**Parental Attitudes, Intentions, Decisions, and Psychological Wellbeing Regarding COVID-19 Vaccination: Preschool, School-Age, and Adolescent Caregivers**
by Liang-Jen Wang
Selected Research

**Serious harms of the COVID-19 vaccines: a systematic review**
Peter C Gøtzsch, Maryanne Demasi
medRxiv 2022.12.06.22283145; doi: https://doi.org/10.1101/2022.12.06.22283145

**Cholera past and future in Nigeria: are the Global Task Force on Cholera Control’s 2030 targets achievable?**
Gina E C Charnley, Sebastian Yennan, Chinwe Ochu, Ilan Kelman, Katy A M Gaythorpe, Kris A Murray
medRxiv 2022.12.06.22283154; doi: https://doi.org/10.1101/2022.12.06.22283154

**Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine**
medRxiv 2022.12.05.22282933; doi: https://doi.org/10.1101/2022.12.05.22282933

**Strategies and interventions to strengthen pharmacovigilance systems in low- and middle-income countries: a scoping review**
Olga Menang, Andrea de Soyres-Kuemmerle, Karen Maigetter, Christian Burri
medRxiv 2022.12.06.22283123; doi: https://doi.org/10.1101/2022.12.06.22283123

**COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting**

**Understanding the impact of disease and vaccine mechanisms on the importance of optimal vaccine allocation**
Isobel R. Abell, James M. McCaw, Christopher M. Baker
medRxiv 2022.06.30.22277126; doi: https://doi.org/10.1101/2022.06.30.22277126 Revision

**Monkeypox knowledge, concern, willingness to change behaviour, and seek vaccination: Results of a national cross-sectional survey**
James MacGibbon, Vincent Cornelisse, Anthony K J Smith, Timothy R Broady, Mohamed A Hammoud, Benjamin R Bavinton, Heath Paynter, Matthew Vaughan, Edwina J Wright, Martin Holt
medRxiv 2022.12.01.22282999; doi: https://doi.org/10.1101/2022.12.01.22282999
The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as A Case Study
Manuela Di Fusco, Diana Mendes, Lotte Steuten, David E Bloom, Michael Drummond, Katharina Hauck, Jonathan Pearson-Stuttard, Rachel Power, David Salisbury, Adrian Towse, Julie Roiz, Gabor Szabo, Jingyan Yang, Kinga Marczell
medRxiv 2022.12.02.22283046; doi: https://doi.org/10.1101/2022.12.02.22283046

Evaluating primary and booster vaccination prioritization strategies for COVID-19 by age and high-contact employment status using data from contact surveys
Ethan Roubenoff, Dennis Feehan, Ayesha S. Mahmud
medRxiv 2022.12.02.22283040; doi: https://doi.org/10.1101/2022.12.02.22283040

Battle of Polio eradication in the Western Pacific Region in the transition to COVID-19 endemicity
medRxiv 2022.11.30.22282954; doi: https://doi.org/10.1101/2022.11.30.22282954

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 10 Dec 2022]
[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

Trusted Research: a Primer from CPNI
UK Reproducibility Network
Last edited: Dec 10, 2022 UTC
Social and Behavioral Sciences Life Sciences Engineering Business Arts and Humanities Education Medicine and Health Sciences Law Physical Sciences and Mathematics Architecture
Trusted Research is official Government guidance for the UK research sector. It was developed in consultation with academia and jointly published by the Centre for Protection of National Infrastructure (CPNI) and the National Cyber Security Centre (NCSC).

OSF Preprints

Questions of ethics during the Covid-19 pandemic emerging from problems of data fraud and health risks
Tam-Tri Le Ruining Jin Minh-Hoang Nguyen
Last edited: Dec 9, 2022 UTC
Life Sciences Medicine and Health Sciences Social and Behavioral Sciences

In more than two years of the global health crisis of the Covid-19 pandemic, ethical issues regarding health data have been emerging quickly to the central focus of the global scientific community. Many papers have been retracted because of data problems, including those from prestigious journals. F ... OSF Preprints

Open Research: Examples of good practice, and resources across disciplines
Open research is best described as “an umbrella term used to refer to the concepts of openness, transparency, rigor, reproducibility, replicability, and accumulation of knowledge” (Crüwell et al., 2019, p. 3). Although a lot of open research practices have commonly been discussed under the term “ope ...

**Wellcome Open Research**  [to 10 Dec 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 10 Dec 2022]

Selected Research
Research Article  Open Access
**Achieving good health with a low environmental footprint — A comparison of national indicators**  [version 1; peer review: awaiting peer review]
Connor Mustard, et al.

*Background*
Integrated metrics that account for resource use and human health are essential to help identify and support human development pathways that safeguard planetary health. We identify countries that achieved the highest levels of health and development at the lowest cost to Earth’s natural capital and report ecological within-country analyses of associations between indicators of environmental sustainability, human health, and development...

*Systematic Review  Open Access*
**Probiotics for preventing or treating COVID-19: a systematic review of research evidence and meta-analyses of efficacy for preventing death, severe disease, or disease progression**  [version 1; peer review: awaiting peer review]
Jawara Allen, Carlton A. Evans, Sumona Datta

* * * * *

**Think Tanks**

**Brookings**  [to10 Dec 2022]
http://www.brookings.edu/
Latest Research [Selected]
Essay
**17 Rooms: Rejuvenating the Sustainable Development Goals through shared action**
John W. McArthur, Zia Khan, Jacob Taylor, Alexandra Bracken, and Daniel Bicknell
Wednesday, December 7, 2022
Executive summary
The 17 Rooms initiative continues to drive action across all the Sustainable Development Goals (SDGs), using unique approaches to help groups unlock and accelerate diverse paths to progress. In the 17 Rooms 2022 flagship, 17 highly curated working groups, one per SDG, came together to craft “next step” actions on priorities ranging from prototyping digital data cooperatives in South Asia, to updating African food and protein policies, and reimagining the role of education systems in climate action worldwide. Several Rooms brought unconventional allies together to prompt new waves of momentum and new forms of accountability. Several focused on actions to bridge environmental and societal outcomes, while others pursued localized tools to tackle global challenges. Meanwhile, in the spirit of enabling local leadership on the SDGs, 17 Rooms-X (or simply “17-X”) offers a widely accessible approach to help communities of all scales take SDG action into their own hands. In 2023, people around the world are invited to bring their own ideas and direct engagement to the 17 Rooms movement.

Center for Global Development [to 10 Dec 2022]
https://www.cgdev.org/
All Research [Selected]
BRIEFS
Estimating Japan’s Return on Investment from an Ambitious Program to Incentivize New Antibiotics
Rachel Silverman and Adrian Towse
December 08, 2022
Drug-resistant infections kill an estimated 23,210 Japanese citizens every year. The government of Japan is considering a program that would provide minimum guaranteed revenue to the successful developers of new antibiotics. We present the results of a modelling exercise to estimate the likely retur...

BRIEFS
Estimating the UK’s Return on Investment from an Ambitious Program to Incentivize New Antibiotics
Rachel Silverman and Adrian Towse
December 08, 2022
Drug-resistant infections kill an estimated 7,600 UK citizens every year. Without investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from an expanded prog...

BRIEFS
Estimating the EU’s Return on Investment from an Ambitious Program to Incentivize New Antibiotics
Rachel Silverman and Adrian Towse
December 08, 2022
Drug-resistant infections kill an estimated 33,000 EU citizens every year. Without sufficient investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from ince...

BRIEFS
Estimating Canada’s Return on Investment from an Ambitious Program to Incentivize New Antibiotics
Rachel Silverman and Adrian Towse
December 08, 2022
Drug-resistant infections kill an estimated 5,400 Canadian citizens every year. Without sufficient R&D investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI...

Chatham House  [to 10 Dec 2022]
https://www.chathamhouse.org/
Selected Analysis, Comment
No new digest content identified.

CSIS  [to10 Dec 2022]
https://www.csis.org/
Selected Reports, Events
No new digest content identified.

Kaiser Family Foundation  [to10 Dec 2022]
https://www.kff.org/search/?post_type=press-release
Newsroom
COVID-19 Vaccines Could Cost Billions of Dollars More Each Year If the Federal Government Ends Its Bulk Purchasing Program
December 7, 2022  News Release
If the federal government runs out of money to purchase COVID-19 vaccines, the per-dose price likely would skyrocket and could increase spending on vaccines by billions of dollars a year, a new KFF analysis finds. To date, the federal government has spent more than $30 billion on COVID-19 vaccines to...

The Nation’s Largest For-Profit Health Systems Have Typically Had Operating Margins That Meet or Exceed Pre-Pandemic Levels
December 5, 2022  News Release
Despite higher inflation and dwindling COVID-19 relief funding from the federal government, the nation’s largest for-profit health systems so far this year have operating margins that meet or exceed levels in 2019 prior to the pandemic, a new KFF analysis finds. The analysis examines the financial performance of the three...

McKinsey Global Institute
https://www.mckinsey.com/mgi/overview
Latest Research
Pixels of Progress: A granular look at human development around the world
Our world is big and complex, but human progress is still about life on the ground, up close and in detail.
December 7, 2022 – In this new report, we share the findings from a new dataset that breaks the world down into more than 40,000 microregions, a view 230 times more granular than a country perspective. This pixelated version of the world, compiled with cutting-edge statistical techniques like the use of night-time satellite imagery, provides a much more nuanced view of development than previous research, enhancing our understanding of global progress in ways that can help business and governments make better, more targeted decisions.

ODI [Overseas Development Institute] [to 10 Dec 2022]
Publications [Selected]
No new digest content identified.

Pew Research Center [to 10 Dec 2022]
https://www.pewresearch.org/
Latest Publications [Selected]
report | Dec 6, 2022
Social Media Seen as Mostly Good for Democracy Across Many Nations, But U.S. is a Major Outlier
Most think social media has made it easier to manipulate and divide people, but they also say it informs and raises awareness.

short read | Dec 6, 2022
In advanced and emerging economies, similar views on how social media affects democracy and society
People in advanced and emerging economies have mixed feelings about social media’s impact on political life.

Rand [to 10 Dec 2022]
https://www.rand.org/pubs.html
Published Research [Selected]
Journal Article
Misinformation, Anticipated Regret, and Vaccine-Related Behaviors
A national survey (N = 1025) conducted in August 2021 reveals that Americans' belief in misinformation about COVID-19 was negatively associated with vaccine acceptance.
Dec 6, 2022
Jody Chin Sing Wong, Janet Z. Yang

Urban Institute [to 10 Dec 2022]
https://www.urban.org/publications
New Research Publications
Research Report
The Impact of the COVID-19 Public Health Emergency Expiration on All Types of Health Coverage
December 5, 2022

... We estimate that if the PHE expires in April 2023, 18.0 million people will lose Medicaid coverage in the following 14 months. Of those, about 3.2 million children are estimated to transition from Medicaid to separate Children’s Health Insurance Programs, about 3.8 million people will become uninsured, about 9.5 million people will either newly enroll in employer-sponsored insurance after losing Medicaid or transition to employer-sponsored insurance as their only source of coverage after being enrolled in both employer-sponsored insurance and Medicaid sometime during the PHE, and more than 1 million people will enroll in the nongroup market, most of whom will be eligible for premium tax credits in the Marketplace.

World Economic Forum [to 10 Dec 2022]
https://agenda.weforum.org/news/
Media
No new digest content identified.

* * * * *

* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.
Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.